Alan Watt PhD MBA

Science Director

Alan holds a BSc in chemistry, a PhD in drug metabolism and an MBA. Alan has spent more than 30 years in pharmaceutical (Merck, GSK) and biotech (Cellzome, Trident Biopharma, Bicycle Therapeutics) research working to discover drugs within the fields of neuroscience, inflammation, metabolism and cancer. He also co-founded a research-focused business Xenovium Limited, providing leadership for inflammation and metabolic research projects. Such diverse experiences have contributed to both the inspiration and scientific foundation for XenoVida.

Most recently Alan has led a startup biotech, NodThera Limited, specialising in discovering novel anti-inflammatory drugs against new target called the inflammasome for a wide range diseases including diabetes, NASH, osteoarthritis, cancer and Alzheimer's Disease. Alan has published over 50 scientific papers in peer-reviewed journals.

If you would like to find out more about partnering with XenoVida, please use the ENQUIRY button below.